Skip to main content
. 2015 Jul 30;138(1):146–159. doi: 10.1002/ijc.29682

Figure 3.

Figure 3

Kaplan–Meier association (using the median staining level from Supporting Information Table S2 at each time point as a cut‐point) between biomarkers and duration of response (DoR) to fulvestrant (*p < 0.05 using Log Rank test). Responses to any other treatments following fulvestrant progression were not a component of these response data. (a) PR H Score at T2; p = 0.008 for higher PR [mean DoR= 48.2 months (95% CI=36.9–59.5; n = 14)] vs. lower PR [mean DoR= 23.4 months (95% CI= 11.6–35.1; n = 14)]; (b) Bcl‐2% at T2; p = 0.01 for higher Bcl‐2% [mean DoR= 48.4 months (95% CI=38.5–58.4; n = 13)] vs. lower Bcl‐2% [mean DoR= 27.5 months (95% CI= 15.3–39.6; n = 14)]; (c) pHER2c (cytoplasmic) H Score at T1; p = 0.018 for any detectable pHER2c [mean DoR= 16.8 months (95% CI= 10.1–23.5); n = 9] versus no pHER2c [mean DoR= 39.1 months (95% CI= 28.5–49.7; n = 22)]; (d) pEGFRm (membrane) H Score at T2; p = 0.007 for any detectable pEGFRm [mean DoR= 21.1 months (95% CI= 12.5–29.7; n = 11)] vs. no pEGFRm [mean DoR= 48.1 months (95% CI= 36.0–60.3; n = 16)]; (e) Ki67% at T1; p = 0.01 for higher Ki67 [mean DoR= 22.2 months (95% CI= 13.2–31.3; n = 15)] vs. lower Ki67 [mean DoR= 43.1 months (95% CI= 30.6–55.5; n = 16)]; (f) Ki67% at T2; p = 0.027 for higher Ki67 [mean DoR= 24.7 months (95% CI= 11.6–37.9; n = 12)] vs. lower Ki67 [mean DoR= 47.1 months (95% CI= 36.2–58.0; n = 15)].